Ultraviolet (UV) phototherapy is a standard treatment for many inflammatory dermatological diseases, including psoriasis. The systemic effects of UV phototherapy are still not well studied. There are several factors that may affect patient's cardiovascular (CV) risk during UV phototherapy. Atherosclerosis is now known to have an inflammatory origin and to be frequently associated with psoriasis. In this study the investigators aim at studying the effect of psoralen-UVA phototherapy on several biomarkers of CV risk in patients with psoriasis with or without atherosclerosis.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
65
36 sessions of psoralen-ultraviolet A, divided as 3 sessions weekly
Dermatology department - faculty of medicine- Cairo University
Cairo, Egypt
Comparative change in photoinduced oxidation and related change in cardiovascular risk between both risk groups in response to photochemotherapy
Comparison between both risk groups in the amount of change between baseline level and end of study level of oxidized low density lipoprotein
Time frame: day 0 to end of 12 weeks (end of 36 sessions, 3 sessions weekly of photochemotherapy) and/or clinical cure whichever comes first
comparative number of patients with metabolic syndrome after therapy in both groups
Comparison between both risk groups as regards the number of patients with metabolic syndrome
Time frame: end of 12 weeks (end of 36 sessions, 3 sessions weekly of photochemotherapy) and/or clinical cure whichever comes first
Comparative changes in metabolic syndrome component 1: waist circumference
Comparison between both risk groups in the amount of change between baseline level and EOS level of waist circumference
Time frame: day 0 to end of 12 weeks (end of 36 sessions, 3 sessions weekly of photochemotherapy) and/or clinical cure whichever comes first
Comparative changes in metabolic syndrome component 2: arterial blood pressure
Comparison between both risk groups in the amount of change between baseline level and EOS level of arterial blood pressure
Time frame: day 0 to end of 12 weeks (end of 36 sessions, 3 sessions weekly of photochemotherapy) and/or clinical cure whichever comes first
Comparative changes in metabolic syndrome component 3: blood sugar
Comparison between both risk groups in the amount of change between baseline level and EOS level of blood sugar
Time frame: day 0 to end of 12 weeks (end of 36 sessions, 3 sessions weekly of photochemotherapy) and/or clinical cure whichever comes first
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Comparative changes in metabolic syndrome component 4: serum lipids
Comparison between both risk groups in the amount of change between baseline level and EOS level of serum lipids
Time frame: day 0 to end of 12 weeks (end of 36 sessions, 3 sessions weekly of photochemotherapy) and/or clinical cure whichever comes first
Atherosclerotic changes in the high risk group in response to PUVA
comparison of duplex arteriography findings in the high risk group between before and after treatment
Time frame: end of 12 weeks (end of 36 sessions, 3 sessions weekly of photochemotherapy)
Correlation between cutaneous response and systemic response to photochemotherapy in both risk groups
Correlation between PASI score after treatment and other parameters of systemic response (hs-CRP, ox-LDL, metabolic syndrome components)
Time frame: day 0 to end of 12 weeks (end of 36 sessions, 3 sessions weekly of photochemotherapy) and/or clinical cure whichever comes first